Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEODOC
2024-512353-24-01Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XP-DC + tumor lysate + keyhole limpet hemocyanin in ovarian cancer, sponsored by Radboud University Medical Center. Primary endpoint: Immune response induced by XP-DC+TL+KLH. Started Nov 2024; status: completed.
02
Drugs
XP-DC + tumor lysate + keyhole limpet hemocyanin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2024-512353-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512353-24-01.